ArticleNPJ precision oncology2024
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer.
Mai Suzuki et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
7 papers cite it
this papercites it